The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review.
gastrointestinal stromal tumors (gists)
metastatic gist
regorafenib
survival rates
treatment-related toxicity
tyrosine kinase inhibitors (tki)
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
26
07
2022
accepted:
01
09
2022
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
7
10
2022
Statut:
epublish
Résumé
Regorafenib, a multi-kinase inhibitor, has been widely used to treat patients with gastrointestinal stromal tumors (GIST) who failed the initial treatment with imatinib and sunitinib. This systematic review aims to demonstrate the efficacy and safety of regorafenib for patients with metastatic and/or unresectable GIST. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to perform this systematic review. We searched PubMed, Science Direct, and Cochrane databases to identify relevant articles based on predefined selection criteria. The implication of the search strategy results in 776 records from all databases. We excluded conference abstracts, discussion articles, case reports, case series, systematic reviews, and other observational non-intervention studies from the study, along with the articles published in languages other than English. After the screening and quality assessment, 10 studies were selected for final review - two randomized controlled trials and eight non-randomized prospective and retrospective review articles of intervention. Regorafenib improved the survival rates of patients after the failure of imatinib and sunitinib treatment, with an acceptable safety profile. Close monitoring of the patients may be needed to detect and manage the grade 4 or higher adverse events.
Identifiants
pubmed: 36199644
doi: 10.7759/cureus.28665
pmc: PMC9526434
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e28665Informations de copyright
Copyright © 2022, Khachatryan et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2021 Oct 1;39(28):3128-3139
pubmed: 34343033
Lancet. 2006 Oct 14;368(9544):1329-38
pubmed: 17046465
Ann Oncol. 2015 Oct;26(10):2017-26
pubmed: 26034039
J Clin Oncol. 2022 Aug 10;:JCO2200294
pubmed: 35947817
Int J Clin Oncol. 2015 Oct;20(5):905-12
pubmed: 25655899
Support Care Cancer. 2014 Mar;22(3):837-46
pubmed: 24337717
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Drugs. 2020 Mar;80(4):433-439
pubmed: 32100250
J Cell Mol Med. 2010 Jan;14(1-2):42-50
pubmed: 19968734
Am Soc Clin Oncol Educ Book. 2012;:663-8
pubmed: 24451815
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Oncotarget. 2017 Jul 4;8(27):44121-44130
pubmed: 28487491
J Clin Oncol. 2012 Jul 1;30(19):2401-7
pubmed: 22614970
Drugs. 2020 Jul;80(11):1133-1138
pubmed: 32578014
Ann Oncol. 2016 Sep;27(9):1794-9
pubmed: 27371698
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Nat Rev Clin Oncol. 2022 May;19(5):328-341
pubmed: 35217782
Cancer Res Treat. 2017 Apr;49(2):350-357
pubmed: 27456941
Cancer Epidemiol. 2016 Feb;40:39-46
pubmed: 26618334
Pathol Res Pract. 2019 Dec;215(12):152708
pubmed: 31708372
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Oncologist. 2012;17(7):992-7
pubmed: 22643537
J Hematol Oncol. 2021 Jan 5;14(1):2
pubmed: 33402214
Ther Adv Med Oncol. 2012 Sep;4(5):255-70
pubmed: 22942908
Clin Cancer Res. 2009 Dec 15;15(24):7510-7518
pubmed: 20008851
Clin Cancer Res. 2012 Aug 15;18(16):4458-64
pubmed: 22718859
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
Oncologist. 2019 Nov;24(11):e1212-e1218
pubmed: 31036770
Clin Sarcoma Res. 2014 Dec 04;4:17
pubmed: 25905001
Clin Sarcoma Res. 2020 Jan 04;10:1
pubmed: 31911828
Cancer Treat Rev. 2020 Jun;86:101993
pubmed: 32199197
Oncol Lett. 2020 Sep;20(3):2131-2142
pubmed: 32782530
ESMO Open. 2021 Aug;6(4):100222
pubmed: 34352702
Int J Clin Oncol. 2022 Jul;27(7):1164-1172
pubmed: 35435530
Onco Targets Ther. 2018 Oct 02;11:6405-6414
pubmed: 30323618